Adverum Biotechnologies Q1 2024 Adj EPS $(1.50) Misses $(1.40) Estimate
Portfolio Pulse from Benzinga Newsdesk
Adverum Biotechnologies reported a Q1 2024 adjusted EPS loss of $(1.50), missing the consensus estimate of $(1.40) by 7.14%.
May 09, 2024 | 9:21 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Adverum Biotechnologies reported a larger than expected loss for Q1 2024, missing analyst estimates.
Missing earnings estimates typically leads to negative investor sentiment in the short term, potentially causing a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100